title: Bexsero® chronicle.
abstract: Neisseria meningitidis causes globally 1·2 million invasive disease cases and 135,000 deaths per year, mostly in infants and adolescents. A century of traditional vaccinology had failed the fight against the serogroup B meningococcus (MenB), mostly prevalent in developed countries. Eighteen years after the publication of the first complete genome sequence from a living organism, thanks to an innovative genome-based approach named 'reverse vaccinology', the first broadly effective MenB vaccine was licensed for use by the European Medical Agency and other authorities, and is being implemented worldwide. Here we review this long and passionate journey, from the disease epidemiology to novel antigen discovery, from vaccine clinical development to public health impact: two decades of scientific and technological innovation to defeat one of the most sudden and devastating invasive diseases.
authors.forename: George
authors.initials: G
authors.lastname: Vernikos
authors.forename: Duccio
authors.initials: D
authors.lastname: Medini
mesh_terms: D017277:Drug Approval; D049674:History, 21st Century; D006801:Humans; D008589:Meningococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000266:history* / Q000276:immunology* / Q000302:isolation & purification; D009345:Neisseria meningitidis / Q000235:genetics / Q000276:immunology*
chemical_list: C570015:4CMenB vaccine; D022401:Meningococcal Vaccines
keywords: 4CMenB,; Antigen Typing System (MATS); Bexsero,; Meningococcal,; Neisseria meningitidis,; Serogroup B meningitis,